Objectives/Goals: Immune checkpoint inhibitors (IO) have dramatically improved survival outcomes in patients with metastatic melanoma. Still. many patients do not respond these treatments. and others may experience harmful adverse events (irAEs). https://darthomes.shop/product-category/stemware/